Skip to main content
Caplight Logo









Revalia Bio

Revalia Bio

Private
New Haven, ConnecticutHealthcare & Life Scienceshttps://www.revaliabio.com/

Last Round

Grant

Dec 5, 2025

Total Funding Raised

$46.2M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Revalia Bio is a biotechnology company that provides a 'Human Data Trials' platform, enabling drug developers to test therapeutics on functional human organs obtained from deceased donors.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Biotech Equipment, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Data as a Service

AI Layer

Non-AI

Keywords

human organ perfusionpre-clinical testingalternative to animal modelscontract research organizationCROex vivo organ perfusiondrug discovery platformhuman-relevant datapre-clinical CROorgan perfusion technologyhuman organ modelsdrug safety testingdrug efficacy testingex vivo modelsbiotech services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Revalia Bio Comparables

Compare Revalia Bio with similar companies based on industry and business-model similarity.

Revalia Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bexorg
83%
AnaBios
78%
Hesperos Inc.
74%

Revalia Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 5, 2025
SeedSep 4, 2025
Pre SeedOct 17, 2024

Key People

Founding team and executive leadership

Helen H.

Co-Founder And Chief People Officer

Founding Team

Greg Tietjen

Co-Founder and Chief Executive Officer

Founding Team

Revalia Bio Investors

Notable investors and investment history

Revalia Bio investors
InvestorRounds
Connecticut InnovationsSeed, Pre Seed
Sierra VenturesSeed
America's Frontier FundSeed
AFFSeed
Pamir VenturesSeed
BoxOne VenturesSeed
ARPA-HGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Grew 32% QoQ from 28 to 37 employees.

  • Jan 1, 2026

    Secured $30M in government contracts.

Revalia Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Revalia Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Revalia Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Haven, Connecticut
Employee Range37
Year Founded2021
Last FundingDec 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?